Development asset linked to pharma& in public FDA and regional records.
pharma · Multiple Myeloma · Ovarian Cancer
pharma&
pharmaand GmbH
pharma& drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Vienna, AT HQ
2017 Founded
210 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Vienna, AT
- Founded
- 2017
- Employees
- 210
- Programs
- 3
- Drugs
- 16
- Patents
- 0
pharma& pipeline
Portfolio lens on 16 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
pharma& drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to pharma& in public FDA and regional records.
-
Development asset linked to pharma& in public FDA and regional records.
-
Development asset linked to pharma& in public FDA and regional records.
-
Development asset linked to pharma& in public FDA and regional records.
-
Development asset linked to pharma& in public FDA and regional records.
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
panobinostat
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in pharma&'s portfolio. Mechanism: Histone deacetylase inhibitor.
- Mechanism
- Histone deacetylase inhibitor
-
Development asset linked to pharma& in public FDA and regional records.
-
Development asset linked to pharma& in public FDA and regional records.
-
rucaparib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in pharma&'s portfolio. Molecular target: PARP 1, 2 and 3.
- Target
- PARP 1, 2 and 3
- Mechanism
- PARP 1, 2 and 3 inhibitor
-
US regulatory status: approved. Molecular target: PARP 1, 2 and 3.
- Target
- PARP 1, 2 and 3
- Mechanism
- PARP 1, 2 and 3 inhibitor
-
Development asset linked to pharma& in public FDA and regional records.
-
Development asset linked to pharma& in public FDA and regional records.
-
Development asset linked to pharma& in public FDA and regional records.
-
Development asset linked to pharma& in public FDA and regional records.